World Congress on Controversies in Psychiatry sponsorship dec 16.pdfWorld Congress on Controversies in Psychiatry 2 Berlin, Germany - June 17-20, 2010 D ear Friends and Colleagues,

The Academy for Clinical Debates & Controversies in Medicine

www.comtecmed.com/copsy

World Congress onControversiesin Psychiatry

A comprehensive Congress fully devoted to clinical debates and controversial issues in a wide spectrum of psychiatric conditions

Sponsorship and Exhibition P rospectusInvitation to Industry

Berlin, Germany, June 17-20, 2010

World Congress on Controversies in Psychiatry2 B e r l i n , G e r m a n y - J u n e 1 7 - 2 0 , 2 0 1 0

Dear Friends and Colleagues, We take pleasure in inviting you to take part in The First World Congress on Controversies in Psychiatry (COPSY). We would be honored by your participation.

During the “Decade of the Brain,” the field of Psychiatry has witnessed enormous expansion in clinical and basic data. This growth has created a greater need to debate the many controversial issues raised and translate them into clinical practice. This point is emphasized in light of the “creation” of the Neurosciences and the need to negotiate a unique place for Psychiatry in this domain. This is a “Concept Congress” that strives to promote true clinical discussion on unresolved pressing issues between practicing physicians and clinical researchers and allowing ample time for speakers-audience interaction.

This CME approved Congress has the ability to reach “real-life” agreed-upon insights on a wide range of psychiatric issues even when the available data is incomplete. The Congress will highlight up-to-date, evidence-based medicine in Psychiatry, to be presented by internationally acclaimed experts.

We look forward to your positive response. Your presence will create a greater forum dedicated to solving these controversial issues.

Yours sincerely, Prof. Meir Steiner Prof. Julien Mendlewicz Prof. Joseph Zohar

On behalf of the international Scientific Committee

International Scientific Committee

Meir Steiner, MD, PhD, FRCPC, Canada, Chairman Professor of Psychiatry & Behavioural Neurosciences and Obstetrics & Gynecology, McMaster University Professor, Department of Psychiatry and Institute of Medical Sciences Adjunct Scientist,,The Hospital for Sick Children, TorontoFounding Director, Women's Health Concerns Clinic St. Joseph's Healthcare Hamilton Julien Mendlewicz, MD, Ph.D, Belgium, ChairmanProfessor of Psychiatry, Free University of Brussels (President of the European College of Neuropsychopharmacology (ECNP Secretary General of the European Brain Council Joseph Zohar, MD, Israel, ChairmanDirector of Psychiatry A and Anxiety Clinic, Chaim Sheba Medical CenterProfessor of Psychiatry, Tel Aviv University Cyril Höschl, DrSc., FRCPsych., Czech Republic, MemberPresident, European Psychiatric Association Director, Prague Psychiatric Centreaffiliated with Charles University Prof. Dr. med. Hans-Jürgen Möller, Germany, Member Director Clinic for Psychiatry of the University of MunichLudwigs-Maximilians Universität MünchenNussbaumstrasse, Munich

Siegfried Kasper, MD, Austria, MemberDepartment of Psychiatry and Psychotherapy

Medical University Vienna, Wien

3World Congress on Controversies in PsychiatryB e r l i n , G e r m a n y - J u n e 1 7 - 2 0 , 2 0 1 0

Sections:

Bipolar DisordersHeadGuy Goodwin, MD, Ph.D., UKW.A.Handley Professor of PsychiatryHead, University Department, Warneford Hospital, Oxford Anxiety DisordersHeadEric Hollander, MD, USAEsther and Joseph Klingenstein Professor and Chair of PsychiatryDirector, Seaver and NY Autism Center of ExcellenceMount Sinai School of Medicine

Women’s Mental HealthHeadSusan G. Kornstein, MD, USAProfessor of Psychiatry and Obstetrics and Gynecology, Virginia Commonwealth UniversityExecutive Director, VCU Institute for Women's HealthPresident, International Association for Women's Mental HealthEditor-in-Chief, Journal of Women's Health

Local Organizing Committee

HeadIsabella Heuser, MD, Germany Professor of PsychiatryChair of Psychiatry at the Medical School of the Charité Berlin Director of the Clinical and Research Unit of Psychiatry, Hospital Charité Berlin

MembersI. Anghelescu, GermanyM. Bajbouj, GermanyM. Huell, GermanyG. Kronenberg, GermanyA. M. Lindenberg, GermanyD. Naber, GermanyR. Rupprecht, Germany

H.U. Wittchen, Germany

MembersB. Bandelow, GermanyB. Baldwin, UKD.J. Stein, South Africa

MembersP. Blier, CanadaE. Vieta, Spain

L. Von Knorring, Sweden

MembersA. Clayton, USAL. Cohen, USAZ. Dolev, IsraelE. Eriksson, SwedenT. Pearlstein, USAC. Soares, Canada


World Congress on Controversies in Psychiatry4 InterContinental Hotel, Berlin, Germany - June 18-21, 2009 5

World Congress on Controversies in PsychiatryInterContinental Hotel, Berlin, Germany - June 18-21, 2009

Session: NOVEL APPROACHES TO TREATMENT OF DEPRESSION (I)Capsule: Despite pharmacological advances, there is still a need to improve efficacy and tolerance of antidepressant therapies

What is the place for novel antipsychotic drugs? Do antiepileptic drugs have a place in the treatment of depression? Chronopharmacological and chronobiological approaches - how strong is the evidence?

Session: NOVEL APPROACHES TO TREATMENT OF DEPRESSION (II)Capsule: Despite pharmacological advances, there is still a need to improve efficacy and tolerance of antidepressant therapies

Nonpharmacological approaches - do they still have a place?

Debate: Monotherapy or Combination Therapy?Proposition: Combination therapy acts faster and more efficiently than monotherapyOpposition: Start with monotherapy then add! Discussion

ANXIETY DISORDERS Session: PREVENTION IN POSTTRAUMATIC STRESS DISORDER (PTSD) – AN ILLUSION OR A DREAM COME TRUE?Capsule: Can the well-accepted notion of "golden hours" (very early intervention which alters the course, e.g. in CVA etc.) be adopted in psychiatry and in the treatment of PTSD?

Debate: Can PTSD be Prevented?Proposition: Insights gained from neuroscience suggest that early intervention may prevent PTSDOpposition: The emotional response to trauma is a “normal response to an abnormal situation” and no special intervention is neededDiscussionIn the aftermath of trauma exposure, what are the positive and negative procedures?

Session: COGNITIVE-BEHAVIORAL THERAPY (CBT) REVISITEDCapsule: Several guidelines (e.g. NICE) suggest CBT as a first-line option in treatment of anxiety disorders, and plummets pharmaceutical intervention to second place

Debate: Can CBT Replace Psychopharmacological Therapy in Anxiety Disorders?Proposition: Should CBT be a first-line treatment in anxiety disorders?Opposition: Should psychopharmacological treatment remain a first-line treatment in anxiety disorders?DiscussionNeuroscience, CBT and psychopharmacology: Can the treatment be tailored?

Session: ANXIETY DISORDERS TOWARD DSM-V AND ICD-11 – WHAT WILL REMAIN AND WHAT WILL CHANGECapsule: Traditionally, anxiety disorders have been grouped together based on symptomatic presentation of "anxiety"

Debate: Should Obsessive Compulsive Disorder (OCD) and Generalized Anxiety Disorders (GAD) Remain in Anxiety Disorders?

Proposition: The data is not strong enough for radical changesOpposition: Neuroscience, epidemiological and genetic findings support division of anxiety disordersDiscussionThe concept of anxiety spectrumsStress-related disorders

Preliminary Program

BIPOLAR DISORDERSSession: PHENOTYPIC DIFFERENTIATIONCapsule: The boundaries of bipolar disorders are not well defined. Is it a single nosologic entity or a cluster of different syndromes?

Bipolar disorder: Spectrum or nonspectrum? Early onset bipolar disorder - how does it differ from the late onset form? Brain imaging as a diagnostic and therapeutic tool

Debate: Childhood Bipolar Disorder: Myth or Reality? Myth: The diagnosis of childhood bipolar disorder and its very existence is being questionedReality: New studies indicate that childhood bipolar disorder is a real entity DiscussionHow to differentiate bipolar disorder from attention deficient hyperactiviy disorder (ADHD) in children?

Session: THERAPEUTIC INTERVENTIONS IN BIPOLAR DISORDERS (1)Capsule: Various pharmacological approaches are available, but the complexity of bipolar disease renders optimal treatments problematic.

What is the ideal mood stabilizer? Should we use second-generation antipsychotics as mood stabilizers? Should we use anti-epileptics as mood stabilizers? Individualised treatment: Is pharmacogenetics a reality or fantasy?

Session: THERAPEUTIC INTERVENTIONS IN BIPOLAR DISORDERS (2)Capsule: Despite polypharmacy relapses of bipolar disease are frequent

USA versus European guidelines for the treatment of bipolar disorder The place for psychosocial therapies

Debate: Antidepressants Aggravate Bipolar Disorders Yes:No:Discussion

Debate: Proposition: Should bipolar depression be treated differently from unipolar depression? Opposition: Bipolar and unipolar depressions should be treated similarly!Discussion

UNIPOLAR DISORDERSSession: PREDICTION OF TREATMENT-RESISTANT DEPRESSION (TRD) Capsule: Approximately one-third of patients suffering from depression do not respond to adequate antidepressant treatment - can this be predicted?

What are the predictors of TRD and how should it be managed?How should TRD be best defined? What are the clinical and neurobiological predictors? Therapeutic challenges of TRDCan we optimize achieving remission in depression?

Session: THE COMORBIDITY PUZZLE OF DEPRESSIVE DISORDERSCapsule: The great majority of depressed patients suffer from other psychiatric and somatic disorders as well. Why is diagnosis so important?

Psychiatric comorbiditySomatic comorbidity Therapeutic challenges of comorbid depression




Session: NOVEL APPROACHES TO TREATMENT OF DEPRESSION (I)Capsule: Despite pharmacological advances, there is still a need to improve efficacy and tolerance of antidepressant therapies

What is the place for novel antipsychotic drugs? Do antiepileptic drugs have a place in the treatment of depression? Chronopharmacological and chronobiological approaches - how strong is the evidence?

Session: NOVEL APPROACHES TO TREATMENT OF DEPRESSION (II)Capsule: Despite pharmacological advances, there is still a need to improve efficacy and tolerance of antidepressant therapies

Nonpharmacological approaches - do they still have a place?

Debate: Monotherapy or Combination Therapy?Proposition: Combination therapy acts faster and more efficiently than monotherapyOpposition: Start with monotherapy then add! Discussion

ANXIETY DISORDERS Session: PREVENTION IN POSTTRAUMATIC STRESS DISORDER (PTSD) – AN ILLUSION OR A DREAM COME TRUE?Capsule: Can the well-accepted notion of "golden hours" (very early intervention which alters the course, e.g. in CVA etc.) be adopted in psychiatry and in the treatment of PTSD?

Debate: Can PTSD be Prevented?Proposition: Insights gained from neuroscience suggest that early intervention may prevent PTSDOpposition: The emotional response to trauma is a “normal response to an abnormal situation” and no special intervention is neededDiscussionIn the aftermath of trauma exposure, what are the positive and negative procedures?

Session: COGNITIVE-BEHAVIORAL THERAPY (CBT) REVISITEDCapsule: Several guidelines (e.g. NICE) suggest CBT as a first-line option in treatment of anxiety disorders, and plummets pharmaceutical intervention to second place

Debate: Can CBT Replace Psychopharmacological Therapy in Anxiety Disorders?Proposition: Should CBT be a first-line treatment in anxiety disorders?Opposition: Should psychopharmacological treatment remain a first-line treatment in anxiety disorders?DiscussionNeuroscience, CBT and psychopharmacology: Can the treatment be tailored?

Session: ANXIETY DISORDERS TOWARD DSM-V AND ICD-11 – WHAT WILL REMAIN AND WHAT WILL CHANGECapsule: Traditionally, anxiety disorders have been grouped together based on symptomatic presentation of "anxiety"

Debate: Should Obsessive Compulsive Disorder (OCD) and Generalized Anxiety Disorders (GAD) Remain in Anxiety Disorders?

Proposition: The data is not strong enough for radical changesOpposition: Neuroscience, epidemiological and genetic findings support division of anxiety disordersDiscussionThe concept of anxiety spectrumsStress-related disorders

Preliminary Program

BIPOLAR DISORDERSSession: PHENOTYPIC DIFFERENTIATIONCapsule: The boundaries of bipolar disorders are not well defined. Is it a single nosologic entity or a cluster of different syndromes?

Bipolar disorder: Spectrum or nonspectrum? Early onset bipolar disorder - how does it differ from the late onset form? Brain imaging as a diagnostic and therapeutic tool

Debate: Childhood Bipolar Disorder: Myth or Reality? Myth: The diagnosis of childhood bipolar disorder and its very existence is being questionedReality: New studies indicate that childhood bipolar disorder is a real entity DiscussionHow to differentiate bipolar disorder from attention deficient hyperactiviy disorder (ADHD) in children?

Session: THERAPEUTIC INTERVENTIONS IN BIPOLAR DISORDERS (1)Capsule: Various pharmacological approaches are available, but the complexity of bipolar disease renders optimal treatments problematic.

What is the ideal mood stabilizer? Should we use second-generation antipsychotics as mood stabilizers? Should we use anti-epileptics as mood stabilizers? Individualised treatment: Is pharmacogenetics a reality or fantasy?

Session: THERAPEUTIC INTERVENTIONS IN BIPOLAR DISORDERS (2)Capsule: Despite polypharmacy relapses of bipolar disease are frequent

USA versus European guidelines for the treatment of bipolar disorder The place for psychosocial therapies

Debate: Antidepressants Aggravate Bipolar Disorders Yes:No:Discussion

Debate: Proposition: Should bipolar depression be treated differently from unipolar depression? Opposition: Bipolar and unipolar depressions should be treated similarly!Discussion

UNIPOLAR DISORDERSSession: PREDICTION OF TREATMENT-RESISTANT DEPRESSION (TRD) Capsule: Approximately one-third of patients suffering from depression do not respond to adequate antidepressant treatment - can this be predicted?

What are the predictors of TRD and how should it be managed?How should TRD be best defined? What are the clinical and neurobiological predictors? Therapeutic challenges of TRDCan we optimize achieving remission in depression?

Session: THE COMORBIDITY PUZZLE OF DEPRESSIVE DISORDERSCapsule: The great majority of depressed patients suffer from other psychiatric and somatic disorders as well. Why is diagnosis so important?

Psychiatric comorbiditySomatic comorbidity Therapeutic challenges of comorbid depression




Session: TREATMENT RESISTANCECapsule: Treatment-resistant patients require more time in clinics and treatment remains controversial

Debate: Switching vs. AugmentationProposition: Clinical and theoretical background favours "switching"Opposition: Evidence and the "myths" of augmentationDiscussionTreatment tailored to a specific patient

Session: CURRENT USE OF BENZODIAZEPINES (BNZ)Capsule: BNZ have been widely used, but concern has also been raised regarding tolerance and withdrawal

Debate: BNZ for Anxiety – Why are They Coming Back?Proposition: We should keep using BNZ!Opposition: BNZ be abandoned!DiscussionBNZ, half-life and addiction potential

Session: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) AND TRICYCLIC ANTIDEPRESSANTS (TCA) – A SECOND LOOKCapsule: Clinical experience with the use of TCA is diminishing - however, relinquishment may be too early

Debate: Does TCA Play a Role in Modern Psychiatric Treatment?Proposition: Despite diminishing experience, TCAs are still relevant for treatment Opposition: TCAs should be disposed of and should be replaced by SSRIsDiscussionThe practicality of TCA use

WOMEN’S MENTAL HEALTHSession: ANTIDEPRESSANT USE DURING PREGNANCY AND BREASTFEEDING Capsule: Despite accumulating data suggesting the relative safety of antidepressants during the perinatal period, many clinicians are still reluctant to prescribe them

Debate: Are antidepressants given during the perinatal period safe?Yes:No:DiscussionDo safety issues differ in early or late pregnancy?What are the potential risks to the fetus and the newborn?How can a clinician make the best evidence-based, risk-benefit decision?

Session: GENDER AND DEPRESSIONCapsule: Evidence on gender differences in symptoms, prevention and treatment of depression is accumulating

Debate: Does Female Depression Differ from Male Depression? Yes:No:DiscussionDo clinical parameters for diagnosis, prevention and treatment vary?Are new diagnostic female-specific tools reliable? (biomarkers)Is the reproductive state important for treatment and diagnosis?

Session: PRESCRIBING HORMONE REPLACEMENT THERAPY (HRT) DURING MENOPAUSAL TRANSITIONCapsule: Re-evaluation of Women’s Health Initiative (WHI) data on a subset of early menopausal women indicates that the benefits outweigh the risks! Debate: HRT has no Place in the Treatment of Depression During Perimenopause

Yes: HRT has no place in the treatment of perimenopausal women No: Trial of treatment with HRT can be an important tool in overcoming perimenopausal symptoms

Discussion: Putting WHI results in perspectiveAre all HRT similar? Are estrogens alone safer and more effective?For which indication?Should we limit the treatment to early menopause?Short-term or long-term treatment?Alternatives to HRT - are they at all effective?Should psychiatrists refrain from prescribing HRT?

Session: PERINATAL PSYCHIATRIC DISORDERSCapsule: The uniqueness of Perinatal Psychiatric Disorders (PPD) is being invalidated by the APA based on the diagnostic system, but continues to be endorsed by most psychiatrists in other countries

Debate: Are PPD unique?Yes:No:

Session: TREATMENT CHOICES FOR PREMENSTRUAL SYNDROMES (PMS/PMDD) Capsule: Despite the established efficacy of (SSRIs) and (SNRIs) in the treatment of PMDD their use is not universally accepted

Debate: Should antidepressants be prescribed routinely for women with premenstrual complaints?Pros:Cons:

Discussion: Clinical issues in prescribing for PMS/PMDDAre hormonal therapies an option?Should the SSRIs/SNRIs be prescribed continuously, or intermittently (during the late luteal phase only)? How long does a responder need to stay on the medication?Is there any evidence that herbal/alternative treatments work?

Session: DEMENTIA Capsule: The value of sub-classification and the mode of treatment of the various types of dementia (like Mild Cognitive Impairment (MIC), Alzheimer, Vascular Dementia, Lobar Dementia, Lewis Body disease (LB) dementia) are still controversial

Debate: Proposition: Sub-classification of dementia has no therapeutic impact and hence is not neededOpposition: Sub-classification of dementia is important clinically and therapeuticallyShould demented - agitated or psychotic patients be treated with antipsychotic drugs and if so, for how long?

Session: SCHIZOPHRENIA Capsule: Schizophrenia is one of the most common psychiatric diseases yet many questions are still unanswered!

Are Second Generation Antipsychotics (SGA) better than First Generation Antipsychotics (FGA)?Is identification and RX treatment of pordoromal symptoms in schizophrenia possible and justified?

Can cognitive impairment in schizophrenia be characterized and treated?Is administration of 2 antipsychotics ever justified?


World Congress on Controversies in PsychiatryB e r l i n , G e r m a n y - J u n e 1 7 - 2 0 , 2 0 1 0 7

World Congress on Controversies in PsychiatryB e r l i n , G e r m a n y - J u n e 1 7 - 2 0 , 2 0 1 0

Session: TREATMENT RESISTANCECapsule: Treatment-resistant patients require more time in clinics and treatment remains controversial

Debate: Switching vs. AugmentationProposition: Clinical and theoretical background favours "switching"Opposition: Evidence and the "myths" of augmentationDiscussionTreatment tailored to a specific patient

Session: CURRENT USE OF BENZODIAZEPINES (BNZ)Capsule: BNZ have been widely used, but concern has also been raised regarding tolerance and withdrawal

Debate: BNZ for Anxiety – Why are They Coming Back?Proposition: We should keep using BNZ!Opposition: BNZ be abandoned!DiscussionBNZ, half-life and addiction potential

Session: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) AND TRICYCLIC ANTIDEPRESSANTS (TCA) – A SECOND LOOKCapsule: Clinical experience with the use of TCA is diminishing - however, relinquishment may be too early

Debate: Does TCA Play a Role in Modern Psychiatric Treatment?Proposition: Despite diminishing experience, TCAs are still relevant for treatment Opposition: TCAs should be disposed of and should be replaced by SSRIsDiscussionThe practicality of TCA use

WOMEN’S MENTAL HEALTHSession: ANTIDEPRESSANT USE DURING PREGNANCY AND BREASTFEEDING Capsule: Despite accumulating data suggesting the relative safety of antidepressants during the perinatal period, many clinicians are still reluctant to prescribe them

Debate: Are antidepressants given during the perinatal period safe?Yes:No:DiscussionDo safety issues differ in early or late pregnancy?What are the potential risks to the fetus and the newborn?How can a clinician make the best evidence-based, risk-benefit decision?

Session: GENDER AND DEPRESSIONCapsule: Evidence on gender differences in symptoms, prevention and treatment of depression is accumulating

Debate: Does Female Depression Differ from Male Depression? Yes:No:DiscussionDo clinical parameters for diagnosis, prevention and treatment vary?Are new diagnostic female-specific tools reliable? (biomarkers)Is the reproductive state important for treatment and diagnosis?

Session: PRESCRIBING HORMONE REPLACEMENT THERAPY (HRT) DURING MENOPAUSAL TRANSITIONCapsule: Re-evaluation of Women’s Health Initiative (WHI) data on a subset of early menopausal women indicates that the benefits outweigh the risks! Debate: HRT has no Place in the Treatment of Depression During Perimenopause

Yes: HRT has no place in the treatment of perimenopausal women No: Trial of treatment with HRT can be an important tool in overcoming perimenopausal symptoms

Discussion: Putting WHI results in perspectiveAre all HRT similar? Are estrogens alone safer and more effective?For which indication?Should we limit the treatment to early menopause?Short-term or long-term treatment?Alternatives to HRT - are they at all effective?Should psychiatrists refrain from prescribing HRT?

Session: PERINATAL PSYCHIATRIC DISORDERSCapsule: The uniqueness of Perinatal Psychiatric Disorders (PPD) is being invalidated by the APA based on the diagnostic system, but continues to be endorsed by most psychiatrists in other countries

Debate: Are PPD unique?Yes:No:

Session: TREATMENT CHOICES FOR PREMENSTRUAL SYNDROMES (PMS/PMDD) Capsule: Despite the established efficacy of (SSRIs) and (SNRIs) in the treatment of PMDD their use is not universally accepted

Debate: Should antidepressants be prescribed routinely for women with premenstrual complaints?Pros:Cons:

Discussion: Clinical issues in prescribing for PMS/PMDDAre hormonal therapies an option?Should the SSRIs/SNRIs be prescribed continuously, or intermittently (during the late luteal phase only)? How long does a responder need to stay on the medication?Is there any evidence that herbal/alternative treatments work?

OTHER TOPICSSession: DEMENTIA Capsule: The value of sub-classification and the mode of treatment of the various types of dementia (like Mild Cognitive Impairment (MIC), Alzheimer, Vascular Dementia, Lobar Dementia, Lewis Body disease (LB) dementia) are still controversial

Debate: Proposition: Sub-classification of dementia has no therapeutic impact and hence is not neededOpposition: Sub-classification of dementia is important clinically and therapeuticallyShould demented - agitated or psychotic patients be treated with antipsychotic drugs and if so, for how long?

Session: SCHIZOPHRENIA Capsule: Schizophrenia is one of the most common psychiatric diseases yet many questions are still unanswered!

Are Second Generation Antipsychotics (SGA) better than First Generation Antipsychotics (FGA)?Is identification and RX treatment of pordoromal symptoms in schizophrenia possible and justified?

Can cognitive impairment in schizophrenia be characterized and treated?Is administration of 2 antipsychotics ever justified?


Sponsorship Opportunity List

As outlined below, there are a number of opportunities for sponsorship available. In addition to the individual benefits of each package, all sponsors will be acknowledged on the Congress Website and in the final Congress Program. If you are interested in any of the sponsorship opportunities below, please contact the Congress Organizer

Continuing Medical Education (CME)Approved Symposium 30,000 EuroThe Sponsor may provide a grant to support an existing session or suggest a CME-approved session (1.5 - 2 hours) as part of

the Scientific Program.

The expenses of the Symposium’s chairpersons and speakers (registration, accommodation and travel) will be the responsibility

of the Sponsor.

Provided by the Congress

• Symposium hall and standard audio/visual equipment

• Four complimentary registrations (for symposium chairpersons and speakers)

• A 100-word sponsor/product profile will be published in the final Congress Program

• Approximately 12 sq.m exhibition space

Additional space may be obtained at a special, reduced price of 400 Euro per sq.m

• Two complimentary registrations for exhibitors. Additional exhibitor’s registration may be purchased at 350 Euro per person

• One A4 page advertisement, full color, published in the final Congress Program

• The Sponsor's logo will be published on the Congress Website, providing a two-way link

• The Sponsor will be acknowledged in the final Congress Program and the logo will appear on a separate Sponsor Logo page

• The Sponsor’s logo will appear on a Sponsor Board on site

• The Sponsor's brochure will be inserted in the participants' bags

Satellite Symposium (NON-CME APPROVED) 40,000 EuroThe Sponsor may organize an industrial non-CME Satellite Symposium (1.5 - 2 hours) as part of the Scientific Program.

Organizing Committee approval of the content and speakers is required. Date and time of the Symposium will be mutually

agreed upon.


of the Sponsor.



• Five complimentary registrations (for Symposium chairpersons and speakers)




• Two complimentary registrations for exhibitors. Additional exhibitor’s registration may be purchased at 350 Euro per person


• The Sponsor's logo will be published on the Congress Website providing a two-way link



• The Sponsor's brochure will be inserted in the participants’ bags


PRE/POST-Congress Satellite Symposium(NON-CME APPROVED) 50,000 Euro(This option is particularly suited for drug launching and other special events)

The Sponsor may organize an industrial non-CME approved Pre/Post-Congress Satellite Symposium, for 3-4 hours (or more) on

Thursday (June 18th, 2009), just before the official opening of the Congress, or at the end (June 21st, 2009) of the Congress.


of the Sponsor.



• Six complimentary registrations (for symposium chairpersons and speakers)




• Two complimentary registrations for exhibitors. Additional exhibitor's registration may be purchased at 350 Euro per

person


• The Sponsor's logo will be published on the Congress Website, providing a two-way link



• The Sponsor's brochure will be inserted in the participants’ bags

LUNCH (per lunch) 25,000 EuroThe Sponsor may subsidize 'in part' a buffet lunch served on Friday, (June 19th, 2009) and/or on Saturday (June 20th, 2009).


• Four complimentary registrations (for the Sponsor’s staff)

• The Sponsor's logo will appear on a special board at the Lunch venue


• An A4 half-page advertisement, full color, published in the final Congress Program

• The Sponsor's logo will be published on the Congress Website providing a two-way link



• The Sponsor’s brochure will be inserted in the participants' bags

Lunch Symposium (NON-CME APPROVED) 40,000 EuroThe Sponsor may organize an industrial CME Lunch-tailored Symposium, for up to one hour as part of the Scientific Program. Please contact the Congress Organizer to coordinate the details.


Other Sponsorship OpportunitiesIn addition to the major sponsorship opportunities, a range of other sponsorship packages is available to meet various needs.

Welcome Reception: Sole Sponsorship 20,000 Euro A Welcome Reception for all participants will be held on Thursday evening at the Congress venue.

Provided by the Congress• The Sponsor’s logo will appear on a special board at the Welcome Reception venue• A 100-word sponsor/product profile will be published in the final Congress Program• An A4 half-page advertisement, full color, published in the final Congress Program• The Sponsor’s logo will be published on the Congress Website, providing a two-way link• The Sponsor will be acknowledged in the final Congress Program and the logo will appear on a separate Sponsor Logo page• The Sponsor’s logo will appear on a Sponsor Board on site• The Sponsor’s brochure will be inserted in the participants' bags

Congress Program: Sole Sponsorship 15,000 Euro The final Congress Program will include the Scientific Program of the Congress. The Congress Program will be distributed to all participants and will be an invaluable reference book after the Congress

Provided by the Congress• One A4 page advertisement, full color, published on the back cover of the final Congress Program• A 100-word sponsor/product profile will be published in the final Congress Program• The Sponsor's logo will be published on the Congress Website providing a two-way link• The Sponsor will be acknowledged in the final Congress Program and the logo will appear on a separate Sponsor Logo page• The Sponsor’s logo will appear on a Sponsor Board on site


Faculty Dinner: Sole Sponsorship 10,000 EuroA Faculty Dinner will be held for the invited speakers of the Congress.

Provided by the Congress• The Sponsor’s logo will appear on a special board at the Faculty Dinner venue• The Sponsor’s logo will be published on the Congress Website, providing a two-way link• The Sponsor will be acknowledged in the final Congress Program and the logo will appear on a separate Sponsor Logo page• The Sponsor’s logo will appear on a Sponsor Board on site

Internet Café: Sole Sponsorship 10,000 EuroThe Sponsor will provide workstations and technical assistance in the Internet Cafe

Provided by the Congress• Display Sponsor logo/information on screensaver• Display Sponsor logo/information on screen background• Distribute mouse pads and related promotional gifts at the cyber center• The Sponsor’s logo will be published on the Congress Website, providing a two-way link• The Sponsor will be acknowledged in the final Congress Program and the logo will appear on a separate Sponsor Logo page• The Sponsor’s logo will appear on a Sponsor Board on site

Participant Bags: Sole Sponsorship 10,000 EuroThe sponsor is asked to kindly provide the participants bags for the Congress themselves. The bags will be distributed to each participant of the Congress.

Provided by the Congress• The Sponsor's brochure/s will be inserted in the participants' bags• The Sponsor's logo will be published on the Congress Website, providing a two-way link• The Sponsor will be acknowledged in the final Congress Program and the logo will appear on a separate Sponsor Logo page• The Sponsor’s logo will appear on a Sponsor Board on site

CD-ROM 10,000 EuroThe CD-ROM will contain all of the COPSy Congress abstracts and will be distributed to all the participants from the Sponsor’s exhibition booth. An exchange voucher (printed by the Sponsor) will be placed in the Congress kit.

Provided by the Congress• Exclusive advertisement on the cover of the voucher• Exclusive advertisement on the cover of the CD-ROM cover.

Mini Program: Sole Sponsorship 5,000 EuroA pocket-size Program together with their registration bags will be distributed to all participants.

Provided by the Congress• The Sponsor’s exclusive advertisement on the back cover of the Mini Program • The Sponsor's logo will be published on the Congress Website, providing a two-way link• The Sponsor will be acknowledged in the final Congress Program and the logo will appear on a separate Sponsor Logo page• The Sponsor’s logo will appear on a Sponsor Board on site


Translation from English 5,000 EuroSimultaneous Translation from English to any required language (Cost per hall per day)

Provided by the Congress• The Sponsor’s logo will appear on a special board in the hall• The Sponsor's logo will be published on the Congress Website, providing a two-way link• The Sponsor will be acknowledged in the final Congress Program and the logo will appear on a separate Sponsor Logo page• The Sponsor’s logo will appear on a Sponsor Board on site

Congress Lanyard: Sole Sponsorship The Sponsor provides printed lanyards for the name badges 3,000 EuroCongress provides the printed lanyards for the name badges 6,000 EuroProvided by the Congress• The Sponsor/product name, logo or text printed on lanyards• The Sponsor’s logo will be published on the Congress Website, providing a two-way link• The Sponsor will be acknowledged in the final Congress Program and the logo will appear on a separate Sponsor Logo page• The Sponsor’s logo will appear on a Sponsor Board on site

European speaker: 3,000 EuroThe Sponsor may support in part the expenses of one or more invited European Speaker.Expenses include registration, accommodation and travel.

Provided by the Congress• The Sponsor’s logo will be published on the Congress Website, providing a two-way link• A half-page advertisement, full color, will be published in the final Congress Program• The Sponsor will be acknowledged in the final Congress Program, and the Sponsor’s logo will appear on a separate Sponsor Logo page• The Sponsor’s logo will appear on a Sponsor Board on site

Non-european speaker: 6,000 EuroThe Sponsor may support in part the expenses of one or more invited Non-European Speaker. Expenses include registration, accommodation and travel.

Provided by the Congress• The Sponsor’s logo will be published on the Congress Website, providing a two-way link• An A4 half-page advertisement, full color, will be published in the final Congress Program• The Sponsor’s brochure will be inserted in the participants’ bags• The Sponsor will be acknowledged in the final Congress Program, and the Sponsor’s logo will appear on a separate Sponsor Logo page• The Sponsor’s logo will appear on a Sponsor Board on site

Prizes for Outstanding Abstracts 3,000 EuroSix prizes of 500 Euro each will be presented to six of the most outstanding abstracts/posters. This will be announced before the congress, on the Website and to all the participants.The Sponsor’s representative will be invited to attend the prize giving

Provided by the Congress• The Sponsor’s logo will be published on the Congress Website, providing a two-way link• The Sponsor will be acknowledged in the final Congress Program and the logo will appear on a separate Sponsor Logo page• The Sponsor’s logo will appear on a Sponsor Board on site


Writing Pads and Pens 3,000 EuroThe Sponsor will provide the participants notepads and pens.This can be an effective high-profile sponsorship opportunity for a drug launch or for immediate brand recognition.

Provided by the Congress• The Sponsor’s logo will be published on the Congress Website, providing a two-way link• The notepads and pens will bear the sponsor's company product/logo and will be distributed in the Congress bags.

Brochure Insert 3,000 EuroBased on the specifications of the sponsor, a brochure will be inserted in the Congress bag. The bag will be distributed to all of the participants of the Congress.

Provided by the Congress• The Sponsor’s logo will be published on the Congress Website, providing a two-way link


General Information

RegistrationEarly RegistrationUntil January 1, 2010

Late RegistrationAfter January 1, 2010

From June 13, 2010 and on

site

Participants Physicians & scientists

540 Euro 590 Euro 650 Euro

Residents* 320 Euro 380 Euro 420 Euro

Accompanying Persons 140 Euro

VenueBerlin, Germany

Congress Organizer Congress Organizers and SecretariatComtecMed53 Rothschild Blvd.PO Box 68, Tel Aviv 61000, IsraelTel: 972-3-5666166Fax: 972-3-5666177Email: [email protected]

Liability and InsuranceThe organizer is not liable whatsoever for injuries or damages involving persons and/or property during the Congress. Participants are advised to issue their own personal travel and health insurance for their trip.

Language The official language of the Congress is English.

Sponsorship and ExhibitionComtecMed c/o Lina Deshilton53 Rothschild Boulevard, PO Box 68Tel Aviv, 61000, IsraelTel: +972 3 5666166 Fax: +972 3 5666177Email:[email protected]: www.comtecmed.com/copsy

A professional exhibition will be held at the Venue in conjunction with the Congress. The floor plan has been designed so as to maximize the exhibitors’ exposure to the delegates. Coffee breaks will be held in this exhibition area.Exhibition spaces will be released for general sale six months prior to the opening date of the Congress. Prior to this date, sponsors will have exclusive rights for space selection.

*Refers to non-tenured junior scientists. Registration form must be accompanied by documentation of residency or a letter from the head of department confirming their status. The letter should be on the department letterhead and addressed to the Registration Department of the Congress. Registration includes: Participation in scientific sessions, Congress bag, Program and Abstract Book, all printed material of the Congress, invitation to the Get-Together Reception, coffee breaks, lunch on Friday and Saturday.Special Group Registration Policy is available upon request.

Accommodation We have managed to book the best available allocation in major hotels in Berlin that will enable us to comply with all of your future accommodation requests.

We have negotiated the best available special group rates for the companies. If your company is interested in booking hotel accommodation ComtecMed will be pleased to negotiate the rates and allocation for you.

Liability and InsuranceThe organizer carries no liability whatsoever for injuries or damages involving persons and/or property during the Congress. Participants are advised to issue their own personal travel and health insurance for their trip.


Sponsorship Booking Form

ComtecMed – Medical Congresses Fax: +972 3 566617753 Rothschild Boulevard Tel: +972 3 5666166P.O. Box 58 Email: [email protected] Tel Aviv 61000, Israel Website: www.comtecmed.com/copsy

Contact Name

Company Name

Address

Post/Zip Code Country

Telephone Fax

Email Website

I would like to book the following Sponsorship items:

I would like to book Exhibition space:

Sponsor Booth at 400 Euro per sq.m (Minimum Booth Size: 5x3 sq.m) Non-Sponsor Booth at 800 Euro per sq.m (Minimum Booth Size: 5x3 sq.m)

Please call me to discuss the sponsorship package

Please send me a sponsorship contract and first 50% deposit invoice.

Signature Date

Sponsorship item Price

Pre-Congress Satellite Symposium Package 50,000 EuroLunch Symposium 40,000 EuroSatellite Symposium Package 40,000 EuroCME-Approved Symposium Package 30,000 EuroLunch 25,000 EuroWelcome Reception 20,000 EuroCongress Program Book 15,000 EuroCD-ROM 10,000 EuroFaculty Dinner 10,000 EuroInternet Café 10,000 EuroParticipants Bags 10,000 EuroCongress Lanyards 6,000 or 3,000 EuroEuropean Speaker 3,000 EuroNon-European Speaker 6,000 EuroMini/Pocket Program 5,000 EuroTranslation from English 5,000 EuroWriting Pads and Pens 5,000 EuroBrochure Insert 3,000 EuroPrizes for Outstanding Abstracts 3,000 Euro

Berlin

www.comtecmed.com/[email protected]

Comtec Spain

Bailén, 95-97, pral.1.a – 08009

Barcelona, Spain

Tel. +34-93-2084445

Fax. +34-93-4579291

Email: [email protected]

Comtec China

175 Xiang Yang Road South,

Shanghai 200031, China

Tel. +86-21-54660460

Fax. +86-21-54660450

Email: [email protected]

Headquarters and Administration53 Rothschild BoulevardPO Box 68, 61000 Tel Aviv, IsraelTel. +972-3-5666166Fax.+ 972-3-5666177 Email: [email protected]

Documents

World Congress on Controversies in Psychiatry sponsorship dec 16.pdfWorld Congress on Controversies in Psychiatry 2 Berlin, Germany - June 17-20, 2010 D ear Friends and Colleagues,